title: [New developments in the treatment of diabetes and hyperlipidemias].
abstract: Diabetes mellitus is a still growing disease. New diagnostic criteria lowered the cut off value to 126 mg/dl, in order to detect more rapidly diabetes and its complications. The treatment of diabetes 2 by the classic oral antidiabetic drugs (sulfamides and biguanides) is completed by intestinal glycosidases inhibitors and thiazolidendiones. These last drugs seem very attractive because they decrease insulin resistance in obese, diabetics. Their hepatic side effects must be however under control. Better knowledge of non lipidic effects of statins on the arterial wall and the discovery of the action of fibrates on PPAR (Peroxisome Proliferator Activated Receptors) improved strongly the therapeutic management of hyperlipidemias. Recent intervention studies have demonstrated the necessity to treat vigorously dysipidemias.
authors.affiliation: Service de Médecine Interne, C.H.U. de Tivoli, La Louvière.
authors.forename: J
authors.initials: J
authors.lastname: Ducobu
mesh_terms: D003920:Diabetes Mellitus / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006949:Hyperlipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008403:Mass Screening / Q000379:methods; D011322:Primary Prevention
chemical_list: D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents